

May 5, 2026

Financial Supplement

First Quarter 2026

NASDAQ: VMD

The logo for VieMed, featuring the word "VieMed" in a white, italicized sans-serif font. A white curved line arches over the letters "ie" and "Me", resembling a stylized wave or a protective shield.

Disclaimers

Forward Looking Statements

Certain statements contained in this Financial Supplement may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue, Adjusted EBITDA and capital expenditures guidance for 2026 and capital allocation priorities, including share repurchases, liquidity position, free cash flow generation, and strategic growth opportunities, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, claims resulting from such events or concerns; the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this Financial Supplement are made as of the date of this Financial Supplement and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

This Financial Supplement contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company's future GAAP results. The Company's financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.

Non-GAAP and Other Financial Information

This presentation includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company's consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies.

Reconciliations between GAAP and non-GAAP financial information are provided within this financial supplement.

Key Themes for Q1 2026

Strong revenue growth across core services, including continued diversification in sleep and maternal health, combined with a more capital-efficient business mix, drove durable free cash flow generation and supported capital return and deleveraging

- Revenue increased 28% year-over-year
- Sleep platform momentum remained strong, with patients up 57% year-over-year and new patient starts up 42%, supporting growth visibility
- Ventilator patient growth remained stable at 2% year-over-year
- Adjusted EBITDA grew 12% year-over-year to \$14.3M, with the prior year period benefiting from a \$2.7M non-recurring gain related to the ventilator return program.
- Generated \$8.1 million of operating cash flow and \$2.6 million of free cash flow
- Repurchased 150,000 shares for \$1.4 million and reduced debt through \$3.2 million of term loan repayments, continuing disciplined capital allocation

Financial and Operational Highlights

(expressed in thousands of U.S. Dollars, except operational information).

For the quarter ended:	3/31/26	12/31/25	9/30/25	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24
Financial Information:								
Revenue	\$75,414	\$76,181	\$71,914	\$63,056	\$59,129	\$60,695	\$58,004	\$54,965
Gross Profit	\$42,827	\$44,103	\$41,345	\$36,731	\$33,279	\$36,138	\$34,371	\$32,892
Gross Profit %	57%	58%	57%	58%	56%	60%	59%	60%
Net Income attributable to Viemed Healthcare, Inc.	\$2,582	\$5,639	\$3,513	\$3,157	\$2,625	\$4,316	\$3,878	\$1,468
Cash and Cash Equivalents (As of)	\$9,762	\$13,501	\$11,123	\$20,016	\$10,160	\$17,540	\$11,347	\$8,807
Total Assets (As of)	\$197,361	\$199,154	\$202,360	\$184,603	\$178,079	\$177,069	\$169,526	\$163,947
Adjusted EBITDA ⁽¹⁾	\$14,311	\$18,203	\$16,121	\$14,287	\$12,765	\$14,242	\$13,954	\$12,813
Operational Information:								
Vent Patients ⁽²⁾	12,089	12,259	12,372	12,152	11,809	11,795	11,374	10,905
PAP Therapy Patients ⁽³⁾	35,938	34,528	31,891	26,260	22,899	21,338	19,478	17,349
Sleep Resupply Patients ⁽⁴⁾	33,661	36,561	33,518	25,246	22,941	24,478	22,143	20,185

⁽¹⁾ Refer to "Adjusted EBITDA" in this presentation for the definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure.


⁽²⁾ Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

⁽³⁾ PAP Therapy Patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter.


⁽⁴⁾ Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter.

Service, Payor and Revenue Mix


Q1 2026




PAYOR MIX




REVENUE MIX




Q1 2025



PAYOR MIX



REVENUE MIX



Revenue Highlights

For the quarter ended	3/31/26	12/31/25	9/30/25	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24
Rental Revenue (expressed in thousands of USD):								
Ventilators, non-invasive & invasive	\$35,360	\$35,888	\$34,883	\$33,819	\$32,159	\$33,173	\$31,772	\$30,445
Other home medical equipment rentals	\$16,198	\$16,200	\$15,401	\$13,823	\$12,962	\$13,047	\$12,459	\$12,211
Sales & Service Revenue (expressed in thousands of USD):								
Equipment and supply sales	\$17,488	\$17,521	\$15,700	\$9,514	\$7,519	\$8,940	\$8,440	\$7,378
Service revenues	\$6,368	\$6,572	\$5,930	\$5,900	\$6,489	\$5,535	\$5,333	\$4,931
Total revenues	\$75,414	\$76,181	\$71,914	\$63,056	\$59,129	\$60,695	\$58,004	\$54,965
Rental Revenue (% of Total revenue):								
Ventilators, non-invasive & invasive	46.9%	47.1%	48.5%	53.6%	54.4%	54.7%	54.8%	55.4%
Other home medical equipment rentals	21.5%	21.3%	21.4%	21.9%	21.9%	21.5%	21.5%	22.2%
Sales & Service Revenue (% of Total revenue):								
Equipment and supply sales	23.2%	23.0%	21.8%	15.1%	12.7%	14.7%	14.6%	13.4%
Service revenues	8.4%	8.6%	8.3%	9.4%	11.0%	9.1%	9.2%	9.0%
Total revenues	100%	100%	100%	100%	100%	100%	100%	100%

Liquidity Metrics

(expressed in thousands of U.S. Dollars)

For the period ended	3/31/26	12/31/25	12/31/24
Cash on hand	\$ 9,762	\$ 13,501	\$ 17,540
Working Capital	\$ 9,105	\$ 7,437	\$ 15,554
Long Term Debt	\$ 8,334	\$ 11,291	\$ 3,589

Positioned for growth

- The Company maintains a healthy balance sheet with effectively no net debt as of March 31, 2026, providing significant financial flexibility.
- As of March 31, 2026, the Company had \$46 million in unfunded commitments available under its existing credit facilities, supporting our capital allocation strategy.

Free Cash Flow

Reconciliation from GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow

We present non-GAAP free cash flow for the current quarter and trailing twelve months (TTM) as a supplemental liquidity measure. Management believes free cash flow provides investors with useful insight into the company's ability to generate cash, fund growth initiatives, and return capital to shareholders. Free cash flow is defined as net cash provided by operating activities, as reported under U.S. GAAP, less net capital expenditures (Net CAPEX). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment in order to reflect both outflows and inflows associated with routine equipment turnover. Trailing twelve months (TTM) free cash flow is calculated by aggregating the last four quarters, each calculated using the methodology described above.

(expressed in thousands of U.S. Dollars)

	TTM 3/31/26	For the quarter ended			
		3/31/26	12/31/25	9/30/25	6/30/25
Net cash provided by operating activities	\$ 57,133	\$ 8,071	\$ 18,441	\$ 18,367	\$ 12,254
Less:					
Purchase of property and equipment	(31,214)	(6,712)	(8,737)	(7,636)	(8,129)
Proceeds from sale of property and equipment	<u>10,425</u>	<u>1,227</u>	<u>1,125</u>	<u>1,671</u>	<u>6,402</u>
Net CAPEX	(20,789)	(5,485)	(7,612)	(5,965)	(1,727)
Free cash flow	\$ 36,344	\$ 2,586	\$ 10,829	\$ 12,402	\$ 10,527

2026 Annual Guidance – Commentary

Core Metrics

- Net revenue of \$312 million to \$320 million (narrowed and raised from \$310 million to \$320 million)
- Adjusted EBITDA of \$65 million to \$69 million (reaffirmed)
- Net capital expenditures of 9% to 10.5% of net revenue (updated from prior range of 10% to 11.5%)

Q1 2026 Performance vs. Seasonal Guidance

- Q1 revenue of \$75.4 million was essentially flat compared to Q4 2025, consistent with the seasonal pattern described at the time of initial guidance
- Sequential revenue growth of 3% to 5% per quarter expected in Q2, Q3, and Q4

Key Assumptions

- Excludes the impact of potential acquisitions
- Revenue range narrowed upward reflecting increased forecasting precision and favorable new patient start trends
- Updated net CAPEX outlook reflects the continued shift toward less capital-intensive service lines

Adjusted EBITDA

Reconciliation of Net Income to Non-GAAP Adjusted EBITDA

Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management.

(expressed in thousands of U.S. Dollars)

For the quarter ended:	3/31/26	12/31/25	9/30/25	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24
Net Income attributable to Viemed Healthcare, Inc.	\$ 2,582	\$ 5,639	\$ 3,513	\$ 3,157	\$ 2,625	\$ 4,316	\$ 3,878	\$ 1,468
Add back:								
Depreciation & amortization	7,621	7,570	7,539	6,891	6,613	6,366	6,408	6,309
Interest expense, net	305	364	507	132	179	147	225	254
Stock-based compensation ^(a)	2,451	2,300	2,180	2,341	2,311	1,521	1,712	1,620
Transaction costs ^(b)	74	139	847	53	85	11	12	221
Impairment of assets ^(c)	-	-	-	-	-	-	125	2,173
Income tax expense	1,278	2,191	1,535	1,713	952	1,881	1,594	768
Adjusted EBITDA	\$ 14,311	\$ 18,203	\$ 16,121	\$ 14,287	\$ 12,765	\$ 14,242	\$ 13,954	\$ 12,813

(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.

(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.

(c) Represents impairments of the fair value of investment and litigation-related assets.